IN10018 + cobimetinib + atezolizumab

IN10018 + cobimetinib + atezolizumab is a three-drug combination being investigated as an anti-cancer therapy. - **IN10018** is a potent, selective, oral small molecule inhibitor of **focal adhesion kinase (FAK)**. Its mechanism targets FAK, a cytoplasmic tyrosine kinase involved in tumor growth, survival, metastasis, and fibrotic progression[3][5][7]. - **Cobimetinib** is a small molecule inhibitor of **Mitogen-activated protein kinase kinase (MEK)**, blocking the MAPK/ERK pathway. - **Atezolizumab** is a humanized monoclonal antibody that blocks **Programmed cell death ligand 1 (PD-L1)**, thereby releasing inhibition of cytotoxic T cells and promoting anti-tumor immune response[2][4][6]. This regimen is experimental and may be intended for use in patients with advanced or metastatic solid tumors (notably melanoma and non-small cell lung cancer) where components have shown complementary mechanisms—targeting intracellular signaling pathways, tumor microenvironment, and immune checkpoints[2][3][5].

Other names

IN10018IN-10018IN 10018cobimetinibatezolizumab